CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 166 enrolled
Drug / intervention
Daridorexant 10 mg +3 moredrug
Likely dose
Daridorexant 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05423717
NCT05423717Phase 2Completed

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder

Idorsia Pharmaceuticals Ltd.·interventional·Posted Jun 21, 2022·Updated Mar 6, 2026

In Brief

A Phase 2 clinical trial evaluating Daridorexant 10 mg, Daridorexant 25 mg, and 2 other interventions for Insomnia. Completed, enrolled 166 participants across 35 sites in 6 countries.

Detailed Summary

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsomnia
CountriesBulgaria, Germany, Italy, Spain, Switzerland, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJun 21, 2022
Enrollment StartSep 6, 2022
Primary CompletionJan 12, 2026
Study CompletionFeb 5, 2026
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.0 years ago

Interventions

Daridorexant 10 mgdrug

Daridorexant will be taken orally, once daily in the evening during the treatment period.

Daridorexant 25 mgdrug

Daridorexant will be taken orally, once daily in the evening during the treatment period.

Daridorexant 50 mgdrug

Daridorexant will be taken orally, once daily in the evening during the treatment period.

Placebodrug

Placebo will be taken orally, once daily in the evening during the treatment period.